Loading
A phase 2 trial of zimberelimab, gemcitabine and cisplatin in gallbladder cancer and other biliary tract cancers, run by Nataliya Uboha, active and no longer recruiting.
Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC) is a phase 2 interventional study registered as NCT06048133 by Nataliya Uboha, with a registry enrolment figure of 33 participants, started 2024-03-08 and due to reach its primary completion in 2026-12. Interventions recorded: Gemcitabine, Cisplatin, Zimberelimab, Quemliclustat. Conditions listed: Biliary Tract Carcinoma, Cholangiocarcinoma, Bile Duct Cancer. Sites: United States. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types), Gemcitabine, Biliary tract cancer (cholangiocarcinoma) and the tag gallbladder-deep-dive.
Shares Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types), Gemcitabine, Biliary tract cancer (cholangiocarcinoma) and the tag gallbladder-deep-dive.
Shares Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types), Gemcitabine, Biliary tract cancer (cholangiocarcinoma) and the tag gallbladder-deep-dive.
Shares Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types), Gemcitabine, Biliary tract cancer (cholangiocarcinoma) and the tag gallbladder-deep-dive.
Shares Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types), Gemcitabine, Biliary tract cancer (cholangiocarcinoma) and the tag gallbladder-deep-dive.
Shares Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types), Gemcitabine, Biliary tract cancer (cholangiocarcinoma) and the tag gallbladder-deep-dive.
Shares Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types), Gemcitabine, Biliary tract cancer (cholangiocarcinoma) and the tag gallbladder-deep-dive.
Shares Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types), Gemcitabine, Biliary tract cancer (cholangiocarcinoma) and the tag gallbladder-deep-dive.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/